Lupin Agrees to Pay Astellas $90 Million in Drug Patent Dispute

Lupin Ltd. settled its dispute with Astellas Pharma Inc. in the midst of trial by agreeing to pay $90 million to resolve their patent dispute over a generic version of a medication for overactive bladder.

Lupin admitted it infringed at least one claim of US Patent Nos. 10,842,780, 11,707,451, 12,059,409 and 12,097,189, according to a consent judgment filed Monday in the US District Court for the District of Delaware. Lupin agreed not to make, sell, or import infringing products in the US until the expiration of the patents, except pursuant to a license that’s part of a ...